These formulations are particularly preferred for chronic management of obesity, as they ensure higher bioavailability compared to oral alternatives and allow the use of long-acting, once-weekly or once-daily therapies
Garver Broccoli sprout compound may restore brain chemistry imbalance linked to schizophrenia
Tarantini G, Scrutinio D, Bruzzi P, Boni L, Rizzon P, Iliceto S: Metabolic treatment with L-carnitine in acute anterior ST segment elevation myocardial infarction
IGF-1 is an endocrine hormone produced by the liver that, along with growth hormone, helps promote normal bone and tissue growth and development
Saxenda is approved for: Adults Adults with obesity (BMI of 30 kg/m or greater) Adults who are overweight (BMI of 27 kg/m or greater) and have at least one weight-related health condition, such as high blood pressure, type 2 diabetes, or high cholesterol Children aged 12 and older Adolescents with obesity who weigh more than 60 kg (132 pounds) Limitations of use Saxenda should not be used together with other medicines that contain liraglutide, such as Victoza, or with any other GLP-1 receptor agonist, such as Ozempic, Wegovy, or Trulicity The safety and effectiveness of Saxenda in children aged 12 to 17 years who have type 2 diabetes have not been established
doi: 10.1038/nature12721 45 GaoK.YangR.ZhangJ.WangZ.JiaC.ZhangF.et al
